tiprankstipranks
MiNK Therapeutics Strikes Convertible Note Deal with Agenus
Company Announcements

MiNK Therapeutics Strikes Convertible Note Deal with Agenus

MiNK Therapeutics (INKT) has released an update.

Don't Miss our Black Friday Offers:

MiNK Therapeutics, Inc. has secured a financial agreement with Agenus Inc., involving a convertible promissory note worth up to $5.0 million. This arrangement allows MiNK Therapeutics to access funds as needed, subject to Agenus’s approval, at an annual interest rate of 2%. The note is repayable on demand after January 1, 2026, and can be settled in cash or equity in the event of a qualified financing event. This move could signal a strategic growth phase for MiNK Therapeutics, potentially piquing the interest of investors monitoring the biotech sector.

For further insights into INKT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMiNK Therapeutics price target lowered to $4 from $8 at Baird
TipRanks Auto-Generated NewsdeskMiNK Therapeutics Reports Q3 Growth and Strategic Advances
TheFlyMiNK Therapeutics reports Q3 EPS (5c), consensus (8c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App